Clinical trial · Interventional
Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma?
La Trogocytose Est-elle un Marqueur prédictif de la réponse Aux Cellules CAR-T Dans Les Lymphomes Diffus à Grandes Cellules B ?
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
CAR-T cell therapy has improved survival in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL R/R). However, only 65% of patients achieve a complete metabolic response after this treatment. To date, there is no predictive test for therapeutic response after injection of CAR-T cells. Recent studies have shown that the level of trogocytosis by immune cells correlates with the persistence of tumor cells in patients with hematological malignancies. Our main objective is to identify a phenotypic "signature" of trogocytosis predictive of therapeutic response 6 months after injection of CAR-T cells for DLBCL.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in patients | Other | — | UNRESOLVED |
| Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in volunteers | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- OTHER
- label
- Patients
- description
- Blood sample for Flow cytometry analysis
- interventionNames
- Other: Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in patients
- type
- OTHER
- label
- healthy volunteer donor
- description
- Blood sample for Flow cytometry analysis
- interventionNames
- Other: Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in volunteers
Primary outcomes (1)
- measure
- Identification of a phenotypic "signature" of trogocytosis predictive of failure to achieve a complete metabolic response for patients with diffuse large B-cell lymphoma.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * For patients * Patient who has given free and informed consent in writing for inclusion in the non-interventional CART-BANK protocol, and orally for the CARTROG protocol, * Patients over 18 years of age at the time of inclusion, * Diagnosis of LDGCB, * Decision to treat with anti-CD19 CAR-T cells, * Patient affiliated to or benefiting from a social security scheme. * For healthy volunteers: * Given free and informed oral consent for inclusion in the CARTROG protocol, * Donor between 18 and 70 years of age at the time of inclusion, * No history of solid cancer or hematological malignancy, * No known chronic pathology (e.g. hypertension, diabetes, etc.) and no daily treatment, * No surgical treatment within the last 6 months. Exclusion Criteria: * Patients who do not meet all the inclusion criteria, * Pregnant or breast-feeding patient, * Patient unable to follow the procedures and/or frequency of visits planned in the trial, for psychological, family, social or geographical reasons, * Patient unable to consent freely to inclusion, under guardianship, curatorship or safeguard of justice.
References
Publications (0)
Data not yet available